A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer
- 30 September 2005
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 49 (3) , 401-412
- https://doi.org/10.1016/j.lungcan.2005.04.003
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancerAnnals of Oncology, 2005
- Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung CancerClinical Cancer Research, 2004
- Randomized Phase III Study of Gemcitabine and Vinorelbine Versus Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer: From the German and Swiss Lung Cancer Study GroupJournal of Clinical Oncology, 2004
- Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975Journal of Clinical Oncology, 2003
- Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study GroupJournal of Clinical Oncology, 2003
- Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinomaCancer, 2001
- Clinical Pharmacokinetics of VinorelbineClinical Pharmacokinetics, 1996
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958